AITB - AIT Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
4.0400
-0.0600 (-1.46%)
As of 1:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.1000
Open4.1000
Bid0.00 x 0
Ask0.00 x 0
Day's Range4.0400 - 4.1500
52 Week Range2.0500 - 5.6500
Volume4,950
Avg. Volume9,858
Market Cap34.476M
Beta (3Y Monthly)N/A
PE Ratio (TTM)5.11
EPS (TTM)0.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
Trade prices are not sourced from all markets
  • GlobeNewswire28 days ago

    AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019

    PMA filing for treatment of PPHN expected in calendar second quarter 2019 Pivotal Bronchiolitis trial to initiate in calendar fourth quarter 2019 in the US Positive clinical.

  • GlobeNewswirelast month

    AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

    GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on.

  • GlobeNewswirelast month

    AIT Therapeutics Schedules Fiscal Second Quarter 2019 Financial Results Conference Call and Webcast

    Call scheduled for Wednesday, November 14 at 4:30pm Eastern Time NEW YORK, Oct. 31, 2018 -- AIT Therapeutics, Inc. (OTC: AITB), a clinical-stage medical device and.

  • GlobeNewswire2 months ago

    AIT Therapeutics Presented Its High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today presented a poster with data on high-dose in vitro inhaled NO at the North American Cystic Fibrosis Conference, being held October 18-20 in Denver, CO. The poster, entitled: “High-Dose Inhaled Nitric Oxide as a Potential Therapy Against Mycobacterial Abscessus Infection in Cystic Fibrosis,” demonstrated the activity of high-dose NO against various multidrug-resistant clinical isolates of M. abscessus in vitro.

  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswire2 months ago

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    NEW YORK , Oct. 17, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the third quarter 2018 performance ...

  • GlobeNewswire2 months ago

    AIT Therapeutics to Present High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced a poster presentation on inhaled NO at the North American Cystic Fibrosis Conference, being held October 18-20 in Denver, CO. The poster will contain results of high-dose nitric oxide as an antibacterial agent in the treatment of Mycobacterium abscessus complex (MABSC).

  • GlobeNewswire3 months ago

    AIT Therapeutics to Present at the Ladenburg 4th Annual Healthcare Conference

    NEW YORK, Sept. 26, 2018-- AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory ...

  • GlobeNewswire3 months ago

    AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced two poster presentations on inhaled NO at the European Respiratory Society (ERS) International Congress 2018, being held September 15-19 in Paris, France. Data were presented from the Company’s multicenter, randomized, double-blind, placebo controlled study comparing the efficacy of intermittent 160 ppm NO (five 30-minute treatments per day for up to 5 days) plus standard of care (SOC) (typically oxygen and hydration) against SOC alone.  The study evaluated 67 infants diagnosed with bronchiolitis and admitted to 6 hospitals across Israel.